Can a blood pressure pill slow MS disability?
NCT ID NCT07765212
First seen Aug 14, 2026 · Last updated Aug 14, 2026
Summary
This phase 2 trial tests whether indapamide, a common diuretic, can slow the worsening of walking ability in people with progressive multiple sclerosis (MS). Participants take one tablet daily for 12 months, with walking speed measured regularly. The study aims to see if the drug reduces the rate of disability progression in this hard-to-treat form of MS.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- indapamide, a diuretic medication taken as a daily tablet
- What this could lead to
- If successful, this could point toward a new treatment to slow disability progression in people with progressive forms of multiple sclerosis.
- What could go wrong
- This is an early-stage, open-label trial with no placebo group, so results may be inconclusive or not generalizable. Indapamide's safety and effectiveness for MS are unproven.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE SCLEROSIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can we decode the different types of pain in multiple sclerosis?
- Hidden MS progression: can brain scans and blood tests predict it?
- Can Brain-Training apps fix sleep in MS?
- Can an Iron-Based dye reveal hidden inflammation in progressive MS?
- Strumming for the brain: could ukulele lessons sharpen minds in MS?
- AI eye on the brain: a smarter scan for multiple sclerosis?